Orion expects cancer drug to drive 2026 sales growth, shares soar

Orion Oyj

14/01/2026 08:33

** Shares in Orion ORNBV.HE jump around 10% to their highest since October after the Finnish pharma group announced better-than-expected financial outlook for 2026

** It expects revenue to come in a range of 1.90 billion euros- 2.10 billion euros ($2.21 billion - $2.45 billion), compared to Factset consensus of 1.95 billion euros, cited by Jefferies

** It also sees operating profit at 550-750 million euros, versus the 602 million consensus estimate cited by Jefferies

** The revenue outlook implies up to 3% upgrades to consensus, while EBIT up to 8% upgrades to the mid-point, the broker says

** The group sees scope for annual net sales in its prostate cancer drug Nubeqa, its largest product, above 1 billion euros

** If gains hold, Orion shares will see their best day since February 2022; they are at the top of STOXX 600 .STOXX index

($1 = 0.8587 euros)

 (Reporting by Boleslaw Lasocki)

 ((boleslaw.lasocki@thomsonreuters.com; +48 58 769 66 00;))